Cover Image
市場調查報告書

全身性紅斑性狼瘡 (SLE)的市場分析、預測:各產品、分子類型、藥理學性分類、地區

The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027: Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class, and Geography

出版商 Visiongain Ltd 商品編碼 524863
出版日期 內容資訊 英文 152 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全身性紅斑性狼瘡 (SLE)的市場分析、預測:各產品、分子類型、藥理學性分類、地區 The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027: Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class, and Geography
出版日期: 2017年05月08日 內容資訊: 英文 152 Pages
簡介

2017年的全球全身性紅斑性狼瘡 (SLE)的收益規模估計超越5億7000萬美元。

本報告提供全球全身性紅斑性狼瘡 (SLE)的市場調查,疾病及治療概要,各地區的患者人口,主要藥物的銷售額預測,主要產品簡介,分子類型、藥理學性分類、主要各地區/國家的市場分析、預測,產品上市的時間軸,以及主要企業的簡介等彙整。

第1章 報告概要

第2章 簡介:全身性紅斑性狼瘡

第3章 流行病學

  • 盛行率
  • 罹患率
  • 死亡率
  • 住院患者數
  • 門診病人治療
  • 費用
  • HRQOL (Health-Related Quality of Life) 的影響

第4章 市場預測

  • 美國、EU、日本、中國的總人口
  • 美國、EU、日本、中國的SLE盛行率
  • 美國、EU、日本、中國的確診人口
  • 美國、EU、日本、中國的治療中的患者數
  • 價格趨勢
  • Atacicept:銷售額預測
  • Benlysta:銷售額預測
  • Anifrolumab:銷售額預測
  • Lulizumab:銷售額預測
  • Bisibimod:銷售額預測
  • CellCept:銷售額預測
  • Prograf:銷售額預測
  • 主要治療藥整體銷售額

第5章 產品簡介

  • Anifrolumab (AstraZeneca)
  • Atacicept (Merck)
  • Baricitinib (Eli Lilly)
  • Benlysta (GlaxoSmithKline)
  • Blisibimod (Anthera)
  • Lupuzor (ImmuPharma)

第6章 市場預測:各分子類型

  • 小分子
  • 單株抗體
  • 重組蛋白質
  • 市場佔有率
  • 比較分析

第7章 市場預測:各藥理學性分類

  • B細胞標靶治療
  • 干擾素受體拮抗劑
  • CD拮抗劑
  • 其他
  • 市場佔有率
  • 比較分析

第8章 主要國家市場

  • 美國:銷售額預測
  • 日本:銷售額預測
  • 中國:銷售額預測
  • 中南美 (含巴西):銷售額預測
  • 英國:銷售額預測
  • 法國:銷售額預測
  • 德國:銷售額預測
  • 義大利:銷售額預測
  • 西班牙:銷售額預測
  • 加拿大:銷售額預測
  • 亞太地區:銷售額預測
  • 比較分析
  • 市場佔有率

第9章 產品的上市時間軸

  • 美國
  • EU
  • 日本

第10章 企業簡介

  • Anthera
  • GSK
  • ImmuPharma
  • Merck
  • AstraZeneca
  • Eli Lilly
  • 其他

第11章 定性分析

第12章 主要調查結果、總論

第13章 用語

目錄
Product Code: PHA0190

Title:
THE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) MARKET FORECAST 2017-2027
Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class (B-Cell Targeting, Interferon Receptor Antagonists, CD Antagonists, Other) and Geography.

Systemic Lupus Erythematosus - our new study reveals trends, R&D progress, and predicted revenues

Where is the SLE market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 152-page report provides 114 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing SLE market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, there are forecasts for 7 Products, 3 Molecule Types and 4 Pharmacological Classes

Systemic Lupus Erythematosus Market Forecasts to 2027, By Product

  • Atacicept
  • Benlysta
  • Anifrolumab
  • Lulizumab
  • Bisibimod
  • CellCept
  • Prograf

Systemic Lupus Erythematosus Market Forecasts to 2027, By Molecule Type

  • Small Molecules
  • Monoclonal Antibodies
  • Recombinant Proteins

Systemic Lupus Erythematosus Market Forecasts to 2027, By Pharmacological Class

  • B-Cell Targeting Therapies
  • Interferon Receptor Antagonists
  • CD Antagonist Therapies
  • Other Therapies for SLE

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 2 regional and 9 leading national markets:

Regional Markets:

  • LATAM (including Brazil)
  • Asia Pacific

National Markets:

  • The US
  • Canada
  • Germany
  • France
  • The UK
  • Italy
  • Spain
  • Japan
  • China

The report also includes profiles and forecasts for some of the leading companies in the Systemic Lupus Erythematosus market, with a focus on the SLE segment of these companies' operations.

There will be growth in both established and in developing countries. Our analyses show that the developing markets, China in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market.

Leading companies and the potential for market growth

Overall world revenue for SLE will surpass $570m in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing prevalence of autoimmune disease, and increasing ageing population will increase sales to 2027.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the SLE Market report helps you

In summary, our 152-page report provides you with the following knowledge:

  • Revenue forecasts to 2027 for the world Systemic Lupus Erythematosus market and 3 different segmentations, with forecasts for 7 Products, 3 Molecule Types and 4 Pharmacological Classes - discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2027 for 2 regional markets and 9 of the leading national markets - LATAM (Including Brazil), APAC, US, Canada, Germany, UK, France, Italy, Spain, Japan, China,
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Systemic Lupus Erythematosus market and leading companies. You will find data, trends and predictions.

Get our report today The Systemic Lupus Erythematosus (SLE) Market Forecast 2017-2027: Revenue Prospects by Product, Molecule Type (Small Molecules, mAbs, Recombinant Proteins), Pharmacological Class (B-Cell Targeting, Interferon Receptor Antagonists, CD Antagonists, Other) and Geography. Avoid missing out - get our report now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Systemic Lupus Erythematosus (SLE) Market Definition
  • 1.2. Methodology
    • 1.2.1. Primary Research
    • 1.2.2. Secondary Research
    • 1.2.3. Market Evaluation & Forecasting Methodology
  • 1.3. Systemic Lupus Erythematosus (SLE) Report Structure
  • 1.4. Why You Should Read This Report
  • 1.5. How this Report Delivers
  • 1.6. Key Questions Answered by This Analytical Report Include:
  • 1.7. Who is This Report For?
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Systemic Lupus Erythematosus

  • 2.1. Aetiology
  • 2.2. Pathophysiology
  • 2.3. Constitutional
  • 2.4. Prognosis
  • 2.5. Symptoms
  • 2.6. Diagnosis
  • 2.7. Assessing the Health Status of SLE patients
  • 2.8. Current Treatment Options
  • 2.9. Unmet Needs

3. Epidemiology

  • 3.1. Prevalence
  • 3.2. Incidence Rates (New Cases/Year)
  • 3.3. Mortality
  • 3.4. Hospitalizations
  • 3.5. Ambulatory Care
  • 3.6. Costs
  • 3.7. Impact on Health-Related Quality of Life (HRQOL)

4. Systemic Lupus Erythematosus Market Forecast 2017-2027

  • 4.1. Total population in US, EU, Japan and China
  • 4.2. Systemic Lupus Erythematosus Prevalence Rate in US, EU, Japan and China
  • 4.3. Diagnosed Systemic Lupus Erythematosus Population in US, EU, Japan and China
  • 4.4. Systemic Lupus Erythematosus Drug Treated Patients in US, EU, Japan and China
  • 4.5. Pricing Trends of the Market
  • 4.6. Atacicept Sales Forecast 2017-2027
  • 4.7. Benlysta Sales Forecast 2017-2027
  • 4.8. Anifrolumab Sales Forecast 2017-2027
  • 4.9. Lulizumab Sales Forecast 2017-2027
  • 4.10. Bisibimod Sales Forecast 2017-2027
  • 4.11. CellCept Sales Forecast 2017-2027
  • 4.12. Prograf Sales Forecast 2017-2027
  • 4.13. All Key SLE Therapies Sales

5. Product Profiles

  • 5.1. Anifrolumab (AstraZeneca)
  • 5.2. Atacicept (Merck)
  • 5.3. Baricitinib (Eli Lilly)
  • 5.4. Benlysta (GlaxoSmithKline)
  • 5.5. Blisibimod (Anthera)
  • 5.6. Lupuzor (ImmuPharma)

6. SLE Market Forecast By Molecule Type 2017-2027

  • 6.1. Small Molecules Sales Forecast 2017-2027
  • 6.2. Monoclonal Antibodies Sales Forecast 2017-2027
  • 6.3. Recombinant Proteins Sales Forecast 2017-2027
  • 6.4. Comparative Sales Analysis
  • 6.5. Market Share - By Molecule Type

7. SLE Market Forecast by Pharmacological Class 2017-2027

  • 7.1. B-Cell Targeting Therapies Sales Forecast 2017-2027
  • 7.2. Interferon Receptor Antagonist Sales Forecast 2017-2027
  • 7.3. CD Antagonist Therapies Sales Forecast 2017-2027
  • 7.4. Other Therapies for SLE
  • 7.5. Market Share - By Pharmacological Class Sales
  • 7.6. Market Share - By Pharmacological Class Sales
  • 7.7. Comparative analysis - Sales by Pharmacological Class Sales

8. Leading National Markets in the Systemic Lupus Erythematosus Market

  • 8.1. US SLE Sales Forecast 2017-2027
  • 8.2. Japan SLE Sales Forecast 2017-2027
  • 8.3. China SLE Sales Forecast 2017-2027
  • 8.4. LATAM (Including Brazil) SLE Sales Forecast 2017-2027
  • 8.5. UK SLE Sales Forecast 2017-2027
  • 8.6. France SLE Sales Forecast 2017-2027
  • 8.7. Germany SLE Sales Forecast 2017-2027
  • 8.8. Italy SLE Sales Forecast 2017-2027
  • 8.9. Spain SLE Sales Forecast 2017-2027
  • 8.10. Canada SLE Sales Forecast 2017-2027
  • 8.11. APAC SLE Sales Forecast 2017-2027
  • 8.12. Comparative analysis - EU Sales
  • 8.13. Market Share - By EU Countries Sales
  • 8.14. Market Share - By EU Countries Sales
  • 8.15. Comparative analysis - US and EU Sales
  • 8.16. Comparative analysis - China and Japan Sales
  • 8.17. Comparative analysis - APAC and LATAM Sales
  • 8.18. Comparative analysis - Key Market Sales

9. Product Launch timelines

  • 9.1. Timeline of USA Launches
  • 9.2. Timeline of EU Launches
  • 9.3. Timeline of Japan Launches

10. Company Profiles

  • 10.1. Anthera Company Profile
    • 10.1.1. Anthera Company Overview
    • 10.1.2. Anthera Projects Overview
    • 10.1.3. Anthera Recent Deals
  • 10.2. GSK Company Profile
    • 10.2.1. GSK Company Overview
    • 10.2.2. GSK Projects Overview
    • 10.2.3. GSK Recent Deals
  • 10.3. ImmuPharma Company Profile
    • 10.3.1. ImmuPharma Company Overview
    • 10.3.2. ImmuPharma Projects Overview
    • 10.3.3. ImmuPharma Recent Deals
  • 10.4. Merck Company Profile
    • 10.4.1. Merck KGaA Company Overview
    • 10.4.2. Merck Projects Overview
    • 10.4.3. Merck Recent Deals
  • 10.5. AstraZeneca Company Profile
    • 10.5.1. AstraZeneca Company Overview
    • 10.5.2. AstraZeneca Projects Overview
    • 10.5.3. AstraZeneca Recent Deals
  • 10.6. Eli Lilly Company Profile
    • 10.6.1. Eli Lilly Company Overview
    • 10.6.2. Eli Lilly Projects Overview
    • 10.6.3. Eli Lilly Recent Deals
  • 10.7. Other SLE companies

11. Qualitative Analysis of the Systemic Lupus Erythematosus Market

  • 11.1. Strengths of the Systemic Lupus Erythematosus Market
  • 11.2. Weakness of the Systemic Lupus Erythematosus Market
  • 11.3. Opportunities for the Systemic Lupus Erythematosus Market
  • 11.4. Threats for the Systemic Lupus Erythematosus Market
  • 11.5. Political Factors Influencing the Systemic Lupus Erythematosus Market
  • 11.6. Economical Factors Influencing the Systemic Lupus Erythematosus Market
  • 11.7. Social Factors Influencing the Systemic Lupus Erythematosus Market
  • 11.8. Technological Factors influencing the Systemic Lupus Erythematosus market

12. Key Findings and Report Conclusion

  • 12.1. Cost of Therapies in Systemic Lupus Erythematosus
  • 12.2. Geographical Trends of Systemic Lupus Erythematosus Market
  • 12.3. Future of the Systemic Lupus Erythematosus Market

13. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Figures

  • Figure 4.1 Atacicept Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 4.2 Benlysta Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 4.3 Anifrolumab Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 4.4 Lulizumab Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 4.5 Bisibimod Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 4.6 CellCept Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 4.7 Prograf Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 4.8 All Key SLE Therapies Sales 2017-2027
  • Figure 6.1 Small Molecules Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 6.2 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 6.3 Recombinant Proteins Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 6.4 Comparative analysis Sales 2017-2027
  • Figure 6.5 Market Share - By Molecule Type Sales 2022
  • Figure 6.6 Market Share - By Molecule Type Sales 2027
  • Figure 7.1 B- Cell Targeting Therapies Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 7.2 Interferon Receptor Antagonist Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 7.3 CD Antagonist Therapies Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 7.4 Other Therapies in SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 7.5 Market Share - By Pharmacological Class Sales 2022
  • Figure 7.6 Market Share - By Pharmacological Class Sales 2027
  • Figure 7.7 Comparative analysis - Sales by Pharmacological Class Sales 2017-2027
  • Figure 8.1 US SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 8.2 Japan SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 8.3 China SLE Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 8.4 LATAM (Including Brazil) SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 8.5 UK SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 8.6 France SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 8.7 Germany SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 8.8 Italy SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 8.9 Spain SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 8.10 Canada SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 8.11 APAC SLE Market Forecast: Revenues ($m), AGR (%), 2017-2027
  • Figure 8.12 Comparative analysis - EU-5 Sales 2017-2027
  • Figure 8.13 Market Share - By EU-5 Countries Sales 2022
  • Figure 8.14 Market Share - By EU-5 Countries Sales 2027
  • Figure 8.15 Comparative analysis - US and EU-5 Sales 2017-2027
  • Figure 8.16 Comparative analysis - China and Japan Sales 2017-2027
  • Figure 8.17 Comparative analysis - APAC and LATAM Sales 2017-2027
  • Figure 8.18 Comparative analysis - Key Market Sales 2017-2027
  • Figure 10.1 Anthera project overview by development stage
  • Figure 10.2 Anthera project overview by Therapeutic area
  • Figure 10.3 GSK project overview by development stage
  • Figure 10.4 GSK project overview by Therapeutic area
  • Figure 10.5 ImmuPharma project overview by development stage
  • Figure 10.6 Immupharma project overview by Therapeutic area
  • Figure 10.7 Merck project overview by development stage
  • Figure 10.8 Merck project overview by Therapeutic area
  • Figure 10.9 AstraZeneca project overview by development stage
  • Figure 10.10 AstraZeneca project overview by Therapeutic area
  • Figure 10.11 Eli Lilly project overview by development stage
  • Figure 10.12 Eli Lilly project overview by Therapeutic area

List of Tables

  • Table 2.1 Diagnostic Tests for Systemic Lupus Erythematosus
  • Table 2.1 Diagnostic Tests for Systemic Lupus Erythematosus (continued)
  • Table 2.1 Diagnostic Tests for Systemic Lupus Erythematosus (continued)
  • Table 4.1 Total Country Population Forecast (in millions)
  • Table 4.2 Overall Systemic Lupus Erythematosus Prevalence Rate (per 100k population)
  • Table 4.3 Diagnosed Systemic Lupus Erythematosus Population (‘000)
  • Table 4.4 Systemic Lupus Erythematosus Drug Treated Patients
  • Table 4.5 Atacicept Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.7 Benlysta Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.8 Anifrolumab Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.9 Lulizumab Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.10 Bisibimod Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.11 CellCept Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.12 Prograf Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 4.13 All Key SLE Therapies Market Forecast: Revenues ($m) 2017-2027
  • Table 6.1 Small Molecules Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 6.2 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 6.3 Recombinant Proteins Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 6.4 Comparative analysis Market Forecast: Revenues ($m) 2017-2027
  • Table 6.5 Market Share - By Molecule Type Revenues ($m) 2022
  • Table 6.6 Market Share - By Molecule Type Revenues ($m) 2027
  • Table 7.1 B- Cell Targeting Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 7.2 Interferon Receptor Antagonist Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 7.3. CD Antagonist Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 7.4 Other Therapies in SLE Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 7.5 Market Share - By Pharmacological Class Revenues ($m) 2022
  • Table 7.6 Market Share - By Pharmacological Class Revenues ($m) 2027
  • Table 7.7 Comparative analysis - Sales by Pharmacological Class Revenues ($m) 2017-2027
  • Table 8.1 US SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.2 Japan SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.3 China SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.4 LATAM (Including Brazil) SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.5 UK SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.6 France SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.7 Germany SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.8 Italy SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.9 Spain SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.10 Canada SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.11 APAC SLE Sales Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2027
  • Table 8.12 Comparative analysis - EU-5 Revenues ($m) 2017-2027
  • Table 8.13 Market Share - By EU-5 Countries Revenues ($m) 2022
  • Table 8.15 Comparative analysis - US and EU-5 Revenues ($m) 2017-2027
  • Table 8.16 Comparative analysis - China and Japan Revenues ($m) 2017-2027
  • Table 8.17 Comparative analysis - APAC and LATAM Revenues ($m) 2017-2027
  • Table 8.18 Comparative analysis - Key Market Revenues ($m)2017-2027
  • Table 9.1 Timeline of USA Launches
  • Table 9.2 Timeline of EU Launches
  • Table 9.3 Timeline of Japan Launches
  • Table 10.1 Anthera Company Overview
  • Table 10.2 Anthera Key licensing deals
  • Table 10.3 GSK Company Overview
  • Table 10.4 GSK Key Licensing deals
  • Table 10.5 ImmuPharma Company Overview
  • Table 10.6 ImmuPharma Licensing deal
  • Table 10.7 Merck Company Overview
  • Table 10.8 Merck Key Licensing deals
  • Table 10.9 AstraZeneca Company Overview
  • Table 10.10 AstraZeneca Key licensing deals
  • Table 10.11 Eli Lilly Company Overview
  • Table 10.12 Eli Lilly Key licensing deals
  • Table 10.13 Other companies involved in the SLE market
  • Table 10.13 Other companies involved in the SLE market (continued)
  • Table 11.1 Strengths and Weakness of the Systemic Lupus Erythematosus Market
  • Table 11.2 Opportunities and Threats for the Systemic Lupus Erythematosus Market
  • Table 11.3 Political, Economical, Social and technological Factors influencing Systemic Lupus Erythematosus Market

Companies Listed

  • 3SBio
  • AbbVie
  • Ablynx
  • Actelion
  • Active Biotech
  • Alkermes
  • Allergan
  • AMEGA Biotech
  • Amgen
  • AstraZeneca
  • Aurinia Pharmaceuticals
  • Beijing SL Pharmaceutical
  • Biogen
  • BioSense Global
  • Biotest
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Chong Kun Dang
  • CipherPharmaceuticals
  • CSL
  • Eli Lilly
  • GSK
  • Helion Biotech
  • Idera Pharmaceuticals
  • ILTOO Pharma
  • Immungenetics
  • Immunomedics
  • ImmuPharma
  • Incyte
  • Innovent Biologics
  • Intrexon
  • Invion
  • Ionis Pharmaceuticals
  • Japan Tobacco
  • Johnson & Johnson
  • Kadmon
  • Ligand Pharmaceuticals
  • MacroGenics
  • Medsenic
  • Merck
  • Mitsubishi Tanabe Pharma
  • Nano Terra
  • Nektar Therapeutics
  • Neovacs
  • Omeros
  • Ono Pharmaceutical
  • PDL BioPharma
  • Pfizer
  • Resolve Therapeutics
  • Roche
  • Sanofi
  • Seattle Genetics
  • Shenzhen Beike Biotechnology
  • Shire
  • Takeda
  • Teva
  • TheraMAB
  • UCB
  • Weizmann Institute of Science
  • Xencor
  • XTL Biopharmaceuticals

List of Organizations

  • Aarhus University
  • Charité Universitätsmedizin Berlin
  • Development Center for Biotechnology
  • Food and Drug Administration (FDA)
  • Ministry of Health, Labor, and Welfare (MHLW)
  • National Health Service (UK)
  • National Institutes of Health (NIH)
  • University of Leicester
  • University of Miami
  • University of Washington
  • World Health Organization (WHO)
Back to Top